Empagliflozin, a sodium-glucose cotransporter 2 (SGLT-2) inhibitor, could mitigate obesity-induced cardiac dysfunction in mice [121]. This evidence concerns the gene SLC5A2 and obesity due to melanocortin 4 receptor deficiency.